Biopharmaceutical Manufacturing: The Challenge of Global Regulatory Compliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biopharmaceutical Manufacturing: The Challenge of Global Regulatory Compliance
This article provides an overview of regulatory issues facing companies that seek to market their biopharmaceutical agents globally, including a trend toward harmonization of requirements as well as the differences in rules concerning applications, GMP standards, and communication with reviewers.


Pharmaceutical Technology


References

1. History and Future of ICH, http://www.ich.org/cache/html/355-272-1.html, accessed November 1, 2007.

2. Synopsis of ICH Guidelines and Topics, May 18, 2004, http://www.ich.org/cache/compo/276-254-1.html.

3. FDA, Guideline for Drug Master Files (Bethesda, MD, Sept. 1989).

4. S.M. Wheelwright and H. Kosaku, Changes to the Japanese Pharmaceutical Affairs Law, http://pharmalicensing.com/articles/disp/1114519858_426e3932b5e95, accessed Nov. 5, 2007.

5. Committee for Proprietary Medicinal Products, Note for Guidance on Summary of Requirements for Active Substances in Part II of the Dossier (The European Agency for the Evaluation of Medicinal Products, London, UK, Jan. 1998).

6. P. D'Eramo, "Japan's Pharmaceutical Affairs Law (PAL): Opportunities and Challenges," http://www.ispe.org/cs/root/regulatory_resources/regulatory_review_article_archives/february_2007_japans_pharmaceutical_affairs_law_pal_opportunities_and_challenges/, accessed November 5, 2007.

7. Good Clinical Practice — Human Medicinal Products, http://www.emea.europa.eu/Inspections/GCPgeneral.html, accessed Nov. 7, 2007.

8. M.W. Matthews and R. Winslow, "New FDA Rules will Expedite Testing of Drugs," Wall Street Journal: Eastern Edition, Jan. 12, 2006, pp. –B6.

9. FDA, Compliance Program Guidance Manual: Active Pharmaceutical Ingredient Process Inspection (Bethesda, MD, Feb. 13, 2006).

10. R. Horan, "FDA CGMP Inspections," 2005 FDA CGMP China Training Program (Dec. 14, 2005), http://www.fda.gov/cder/meeting/CTP2005.htm, accessed Nov. 4, 2007.

11. A.M. Thayer, "Europe Adopts GMP Regulations," Chem. Eng. News 84 (7), 29–33 (2006).

12. FDA, "Innovation and Continuous Improvement in Pharmaceutical Manufacturing," Pharmaceutical CGMPs for the 21st Century, http://www.fda.gov/cder/gmp/gmp2004/manufSciWP.pdf, accessed Nov. 5, 2007.

13. A. Katsnelson, "FDA and EMEA Pool Scientific Advice," Nat Biotechnol. 22(12), 1490–1491(2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here